Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal brings CHF75 million upfront plus welcome validation after Basilea's break-up with J&J on ceftobiprole.